KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
September 28, 2022 07:30 ET
|
KemPharm
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty...
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
August 11, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.’s President and CEO, to Participate and Provide...
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
August 09, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm to Report Second Quarter 2022 Financial Results
August 04, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 02, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
July 26, 2022 08:30 ET
|
KemPharm
CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
June 01, 2022 08:30 ET
|
KemPharm
Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION,...
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
May 15, 2022 20:00 ET
|
KemPharm
Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease ...
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
May 12, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET Filed Investigational New Drug (IND) application with U.S. Food and Drug...